受体活性修饰蛋白3增强GLP-1介导的胰岛素分泌
bioRxiv : the preprint server for biology
|August 20, 2025
概括
受体活性修饰蛋白3 (RAMP3) 与葡萄糖类-1受体 (GLP-1R) 相互作用,改变其信号,以增强胰岛素分泌. 这一发现可能会带来更好的GLP-1R疗法,并减少副作用.
科学领域:
- 内分泌学
- 分子药理学
- G蛋白结合受体 (GPCR) 信号传递
背景情况:
- 葡萄糖类-1受体 (GLP-1R) 激动剂对糖尿病和肥胖有效,但会引起副作用.
- 受体活性修饰蛋白 (RAMPs) 可以调节GPCR信号和表达,提供减轻不良反应的策略.
- 了解GLP-1R与RAMP的相互作用对于开发更安全,更有效的治疗方法至关重要.
研究的目的:
- 研究GLP-1R与受体活性修饰蛋白3 (RAMP3) 的相互作用.
- 确定RAMP3结合如何影响GLP-1R信号通路和功能结果.
- 探索GLP-1R-RAMP3综合体对代谢疾病的治疗潜力.
主要方法:
- 证实GLP- 1R和RAMP3相互作用的同时免疫沉测试.
- 基于细胞的测定测量 (Ca2+) 调动和循环AMP (cAMP) 生产.
- 在RAMP3表达变化的细胞中对GLP-1刺激时的G蛋白合 (Gαs,Gαq,Gαi) 的分析.
- 使用RAMP3敲除小鼠进行体内研究以评估葡萄糖和胰岛素耐受性.
主要成果:
- 在细胞表面,GLP- 1R与RAMP3形成一个功能性异构体.
- RAMP3表达将GLP-1R信号从正规的cAMP生产转移到Ca2+调动和Gαq/Gαi合.
- 过度表达RAMP3增强了GLP-1介导的葡萄糖刺激胰岛素分泌,而RAMP3淘汰的小鼠显示出葡萄糖和胰岛素耐受性受损.
结论:
- RAMP3 作为GLP- 1R信号的关键调节器,将其活性倾向于胰岛素分泌.
- GLP- 1R- RAMP3复合体是改善血糖控制的有希望的治疗点,并可能减少副作用.
- 这些发现为设计新的GLP-1R向药物提供了基础,通过考虑RAMP相互作用.
相关概念视频
Glucagon-like Receptor Agonists
415
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
415
Dipeptidyl Peptidase 4 Inhibitors
249
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
249
Insulin: The Receptor and Signaling Pathways
1.5K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.5K
Hormones Regulating Blood Glucose
4.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
4.0K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K
Oral Hypoglycemic Agents: Glinides
256
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
256


